With Vascepa’s New CV Claim, Amarin Targets Patients On Other Triglyceride-Lowering Agents

Amarin Corp. PLC’s plan for promoting Vascepa’s (icosapent ethyl) new cardiovascular risk reduction claim includes convincing practitioners to switch patients currently using other triglyceride-lowering agents that have failed to demonstrate a CV outcome benefit.

“A significant part of our education process will also emphasize that with an FDA-approved indication, it makes little sense for patients to continue being treated with earlier generation products, which while they might have lowered triglyceride levels have all failed to demonstrate cardiovascular risk reduction in clinical studies,” chief medical officer Craig